Vibha provides news and analysis for Pink Sheet and Scrip on a broad range of subjects related to companies, including deals, strategy, regulation and policy. Her multimedia content including infographics and podcasts have helped her win internal awards. She brings her education in business management and experience as a senior journalist for AFX-Asia to bear in spotting trends. As an attendee and panelist at conferences, she strives to bring unique insights to the audience. In her spare time, she enjoys travel, photography and blogging.
Latest from Vibha Ravi
US President Trump’s threat of a “25% or higher” import tariff on pharmaceuticals sends ripples through an already uncertain environment. With about half of generics sourced from India, captains of industry read between the lines
US President Trump’s plan for a “25% or higher” tariff on pharmaceuticals promises to have a far-reaching impact, from higher prices and drug shortages to increased onshoring of manufacturing in the US. Is MAGA worth the chaos it might create for MAHA? The Indian industry shares its views.
A US tariff on imports from China raises the spectre of similar action against India, but Aurobindo, the largest generics company in the US by prescriptions dispensed, assures it has alternatives in place. While trials for an opthalmology biosimilar are delayed, supply of other biosimilars to Europe is set to begin in Q2 FY26.
President Trump imposed reciprocal tariffs on countries with duties on US exports 13 February. When asked on 7 February about the impact of US tariffs, Aurobindo said it has alternatives in place to deal with them.
A US tariff on imports from China raises the spectre of similar action against India, but Aurobindo, the largest generics company in the US by prescriptions dispensed, assures it has alternatives in place. While trials for an opthalmology biosimilar are delayed, supply of other biosimilars to Europe is set to begin in Q2 FY26
A Zydus-Takeda joint venture is expected to supply more raw materials to the Japanese major. Meanwhile, a tie-up with CVS Caremark for the sitagliptin franchise is a boost for Zydus’s US sales while the company focuses R&D efforts on rare diseases like ALS and CAPS